Latest addition to program is valuable global NGS resource to IDT and its customers
CORALVILLE, Iowa (September 11, 2020)
— Integrated DNA Technologies (IDT)
, a leading comprehensive genomics solutions provider, announced that Novogene, a world leader in Next Generation Sequencing (NGS) services, has joined the IDT Align℠ Preferred Sequencing Provider Program.
The combination of Novogene’s leading bioinformatics and analysis services with IDT’s high-quality and flexible products offers researchers an invaluable resource for their genomics projects.
The IDT Align Preferred Sequencing Partner Program was established to broaden access to cutting-edge services and solutions that address customer needs and help genomic researchers achieve their project goals. IDT is teaming up with strategic partners to make NGS tools and solutions more accessible, especially for researchers who need to find a sequencing provider tailored to their unique needs. Sequencing options from partners in the Align Program include whole genome sequencing.
“IDT is very pleased to welcome Novogene to our Align Preferred Sequencing Provider Program,” said IDT President Trey Martin. “Their broad range of services and incredible capacity are an ideal fit for our Program. We will work closely together using IDT’s industry-leading NGS products to empower greater discoveries at even higher efficiencies.”
“We are excited to partner with IDT as an Align Preferred Sequencing Provider, as it marks a significant advancement of our mission to see genomics improving life,” said Douglas Zhang, PhD, president of Novogene America. “Many of our clients have worked closely with IDT for many years and this new collaboration will provide many more with access to customized and innovative NGS services that leverage the vast experience and expertise both Novogene and IDT have to accomplish their research goals.”
IDT is widely recognized as an industry leader in DNA writing, and the Company is also delivering innovative and high-performing NGS products
to enable research and discoveries. NGS solutions from IDT feature consistent reliability, customization and scalability that provide customers confidence in their results.
Novogene was founded in 2011 and is headquartered in Beijing, China. In addition to having branches in Hong Kong, Singapore, Japan, United Kingdom, the Netherlands, and the United States, it has genomic sequencing labs at the University of California at Davis (US) and the University of Cambridge (UK).
Novogene's sequencing capacity is among the largest in the world, helping customers who otherwise do not have direct access to sequencing instruments to scale up projects at any volume. Their expertise, global positioning, and customer focus also helps them remain an industry leader in turnaround time.
Follow IDT on Twitter @idtdna
for real-time updates and insights.
Integrated DNA Technologies, Inc. (IDT)
develops, manufactures, and markets nucleic acid products for the life sciences. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its ISO:13485 services, IDT manufactures products used by scientists in researching many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as an industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT was founded in 1987 and has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Research Triangle Park, North Carolina, USA; Leuven, Belgium; and Singapore. For more information, please visit www.idtdna.com
IDT Public Relations
800-328-2661 (US & Canada)
+1 319-626-8400 (outside US)
is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise, and some of the most advanced sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service, and unsurpassed data quality to help our clients realize their research goals. The company has become a world leader in NGS services, with 2,600 employees and multiple locations across the globe. Novogene’s depth of experience has resulted in the ownership of 27 NGS-related patents, as well as publishing of over 4,920 customer research papers, often in well-respected publications such as Nature and Science. For more information, visit en.novogene.com.